Categories: BioTechCareIT
Obulytix leverages phage-derived lysins, enzymes that rapidly cleave bacterial cell walls with extraordinary specificity.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.12.2023 | Seed | $4.32M | - |
Mentions in press and media 3
| Date | Title | Description |
| 27.11.2025 | Obulytix Strengthens Senior Leadership with Key Executive and Board Appointments | Ghent, Belgium – November 27th, 2025 – Obulytix, the biotechnology company pioneering Precision Lysin Therapeutics (PLTs) — a novel class of targeted biologics designed as next-generation antibiotics — today announces the appointment of Guy... |
| 08.10.2024 | Obulytix appoints Dr. Kristof Van Emelen as Chief Executive Officer | Ghent, Belgium, October 1st 2024 – Obulytix, a pre-clinical stage biotech company pioneering phage lysin-based antibiotics to fight antibiotic-resistant infections, announces the appointment of Dr. Kristof Van Emelen as its new Chief Execut... |
| 06.12.2023 | Obulytix raises € 4 million round in Seed funding | Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial i... |
Reviews 0
